Beauty Farm Medical and Health Industry Inc. 2025 Annual Report – Key Highlights and Investor Insights

Beauty Farm Medical and Health Industry Inc. has released its Annual Report for 2025, offering crucial insights into its financial performance, strategy, and shareholder returns that may significantly impact share value.

Key Financial Highlights

• Record Revenue Growth: Revenue surged to RMB 3.00 billion in 2025, up 16.7% YoY from RMB 2.57 billion in 2024. This marks continued rapid growth, with revenue nearly doubling since 2022.
• Profitability: Net profit reached RMB 340.3 million (up 34.8% YoY). The gross profit margin improved to 49.1% from 46.3% last year, reflecting operational efficiency and robust demand.
• Earnings Per Share: Basic EPS rose to RMB 1.38 (2024: RMB 0.99). Diluted EPS was RMB 1.37.
• Assets and Equity: Total assets grew to RMB 5.05 billion, with equity rising to RMB 1.07 billion by year end.
• Dividends: The board proposed a final dividend of HK\$0.72 per share (a 38.5% YoY increase), amounting to HK\$180 million. The company has committed to distributing no less than 50% of net profit as dividends for the next three years, barring special circumstances.
• Adjusted Net Profit: Adjusted net profit (non-HKFRS) was RMB 380.8 million, up from RMB 270.1 million in 2024.

Strategic and Operational Developments

• Digitalisation and AI Investment: Over RMB 200 million invested in IT over five years, forming a 90-person IT team. Launch of proprietary “AI Xiaonai (AI)” – a digital assistant with extensive expertise in TCM, advanced beauty, and sales. This AI is expected to boost service quality and operational efficiency, potentially opening new business frontiers in the sector.
• Shareholder Value Enhancement:
  • In March 2025, the company launched a dedicated capital market value enhancement plan with three pillars:
    • Increasing dividend payout ratio
    • Optimising shareholder structure (notably, CITIC PE Funds exited, replaced by new long-term strategic investors)
    • Enhancing management incentive mechanisms (equity incentive plans tied to revenue/profit targets, with 2025 targets exceeded)
• Share Buyback: In 2025, the company repurchased 940,000 shares on the Stock Exchange for HK\$27.3 million. These shares are held as treasury shares and will not be entitled to dividends, but may be resold, transferred, or cancelled in the future.
• Strong Talent Pipeline: Employee count reached 5,343 at year-end, with total benefit expenses up to RMB 1.21 billion, reflecting both expansion and continued investment in staff incentives and development.
• Inventory and Fund Management: Inventory turnover ratio improved by 30%, and fund management processes were further digitalised for efficiency and risk mitigation.
• Risk Management: Enhanced risk controls across OPEX, treasury, contracts, and investments. Regular operational and risk review meetings are held to dynamically adjust strategies.

Corporate Governance and Compliance

• Governance: Model Code for Securities Transactions adopted and complied with by all directors and senior management. Audit and Remuneration Committees functioning as per Listing Rules, with regular reviews of financials, controls, and remuneration policy.
• Compliance: No material breaches of laws or regulations. No material litigation or government investigation reported.
• Anti-Bribery: No evidence of bribery or kickbacks; controls and training in place for ongoing compliance.
• Shareholder Rights: At least 25% of shares (excluding treasury shares) held by public throughout the year. No pre-emptive rights exist under Cayman law or Articles.

Contractual Arrangements and Regulatory Risks

• VIE Structure: The company operates some PRC medical businesses through contractual arrangements (VIEs) to comply with foreign investment restrictions. Risks include potential regulatory challenges, less robust control compared to direct ownership, and possible tax scrutiny.
• Mitigations: Regular legal and operational reviews, no material incidents as of report date.

Share Incentive and Option Schemes

• Share Incentive Plan: Awards vest in tranches over up to four years, subject to annual performance targets. New grants in December 2024 cover both income and profit improvement for the next three years, aligning management and shareholder interests.
• Share Option Scheme: Options granted (notably 3.19 million options in December 2024, exercise price RMB 12.13) vest based on company performance (2025-2027). Option valuation based on binomial model, with expected volatility between 48% and 52%.

Other Noteworthy Points

• No Convertible Bonds or Debentures: None issued in 2025.
• No Material Litigation: No significant lawsuits or claims pending or threatened as of year-end.
• Banking and Borrowings: No defaults on bank loans or borrowings; no unutilised bank facilities as of year-end.
• Investment Property: Valued at RMB 91.96 million as of year-end.
• Dividend Exclusion: 1,065,000 treasury shares held by the company will not receive dividends.

Potential Price-Sensitive Developments

• Dividend Policy and Payout: The firm’s commitment to a high dividend payout ratio (≥50% of net profit for next three years) and a substantial final dividend increase signals strong confidence in future cash flows and is likely to support or boost share price.
• Share Buybacks: Ongoing buybacks reduce free float and can enhance EPS, potentially supporting the share price.
• Strategic Shareholder Changes: The replacement of a major PE shareholder with new long-term investors may be interpreted positively by the market as a vote of confidence and could reduce perceived overhang risk.
• AI and Digitalisation: Heavy investment in proprietary AI and digital infrastructure, with demonstrated operational efficiency gains, positions the company as an innovation leader in China’s beauty and wellness sector – potentially raising its premium in the eyes of investors.
• Management Incentives Aligned with Performance: Exceeding performance targets and tying compensation to revenue/profit growth aligns management interests with shareholders and may drive continued outperformance.
• Regulatory Risks: Continued reliance on VIE structures for PRC medical business carries inherent regulatory risks which, if materialised, could adversely impact operations and valuation. Investors should monitor developments in Chinese foreign investment law.

Conclusion

Beauty Farm Medical and Health Industry Inc. enters 2026 with robust financial health, a shareholder-friendly dividend policy, ongoing share buybacks, and a clear strategy centered on digital transformation and operational excellence. Shareholders should note the company’s commitment to high dividends, alignment of management incentives, and ongoing investment in AI and digital infrastructure as key drivers of future value. However, regulatory risks inherent in the VIE structure remain an area for close monitoring.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information is based on the company’s 2025 Annual Report and may be subject to change or updates in the future.

View BEAUTYFARM MED Historical chart here